Roche has ended two Huntington’s disease antisense therapy programs co-developed with Ionis after failing to meet key objectives and encountering a safety signal. The company discontinued the Phase 2 GENERATION HD2 study of tominersen and halted a separate trial evaluating RG6496. Roche cited “deeply disappointing” and data-driven outcomes and said the decisions were based on the “totality of data,” while noting the failures coincided by chance. The move follows other Ionis-linked late-stage trouble, including the Wainua (eplontersen) Phase 3 CARDIO-TTRansform failure in transthyretin amyloidosis cardiomyopathy. For Ionis, the sequence underscores how late-stage biology and safety signals can quickly reshape the value of mRNA/oligonucleotide franchises, especially as investors reprice clinical risk across antisense platforms.